Cue Biopharma (CUE) Retained Earnings (2017 - 2026)

Cue Biopharma has disclosed Retained Earnings across 10 years of filings, most recently posting -$526.7 million for Q2 2026.

• In Q2 2026, Retained Earnings fell 45.26% year-over-year to -$526.7 million; the TTM figure through Jun 2026 stood at -$526.7 million (down 45.26% YoY), while the FY2025 annual figure was -$368.5 million, down 7.78% from the prior year.
• Retained Earnings came in at -$526.7 million for Q2 2026 at Cue Biopharma, down from -$368.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$211.7 million in Q1 2022 to a low of -$526.7 million in Q2 2026.
• Average Retained Earnings over 5 years is -$314.4 million, with a median of -$313.5 million recorded in 2024.
• Year-over-year, Retained Earnings declined 7.78% in 2025 and tumbled 45.26% in 2026.
• Over 5 years, Retained Earnings stood at -$250.5 million in 2022, then decreased by 20.26% to -$301.2 million in 2023, then fell by 13.5% to -$341.9 million in 2024, then declined by 7.78% to -$368.5 million in 2025, then slumped by 42.95% to -$526.7 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$526.7 million in Q2 2026, -$368.5 million in Q4 2025, and -$370.1 million in Q3 2025.